Durect shares nosedive on Phase III upset

Durect ($DRRX) disappointed investors with data from a Phase III study of anti-pain drug Posidur that were revealed Thursday, and the developer's share price was down more than 30% as of late this morning. The data failed to show that the drug provided a statistically significant improvement in pain in the 305-patient trial, which studied the safety and efficacy of the drug versus placebo in patients undergoing abdominal surgeries. The study also tested the drug against two comparator treatments in patients who underwent two other types of abdominal surgeries, Dow Jones Newswires reported. Durect release | Article

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.